Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial

• Published in: Diabetes care Vol. 39; no. 10; pp. 1693 - 1701
• Main Authors: Ahrén, Bo, Hirsch, Irl B., Pieber, Thomas R., Mathieu, Chantal, Gómez-Peralta, Fernando, Hansen, Troels Krarup, Philotheou, Areti, Birch, Sune, Christiansen, Erik, Jensen, Thomas Jon, Buse, John B.
• Format: Journal Article
• Language: English
• Published: United States American Diabetes Association 01.10.2016
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Medicine; Clinical trials; Diabetes; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - drug therapy; Double-Blind Method; Drug dosages; Drug Therapy, Combination; Endocrinology and Diabetes; Endokrinologi och diabetes; Female; Glycated Hemoglobin A - analysis; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents - administration & dosage; Injections, Subcutaneous; Insulin; Insulin - administration & dosage; Klinisk medicin; Liraglutide - administration & dosage; Male; Medical and Health Sciences; Medicin och hälsovetenskap; Middle Aged; Placebo effect; Treatment Outcome; Young Adult

To investigate the efficacy and safety of liraglutide added to capped insulin doses in subjects with type 1 diabetes. A 26-week, placebo-controlled, double-blind, parallel-group trial enrolling 835 subjects randomized 3:1 receiving once-daily subcutaneous liraglutide (1.8, 1.2, and 0.6 mg) or placeb...